End Feel -joint end feel - Normal and Abnormal end feel
01.5 belbin aecc advances 2010 for web
1. New Epigenetic Biomarkers of Oropharyngeal Cancer Thomas J. Belbin Department of Pathology 5/21/2010 Science at the heart of medicine
2. 5/21/2010 Science at the heart of medicine Head and Neck Squamous Cell Carcinoma >48K cases, >11K deaths in the US oral cavity, oropharynx, hypopharynx, larynx, nasopharynx tobacco, alcohol, HPV, betel quid etc. surgery, radiation, chemotherapy recurrence in about 50% of patients 5-year survival rate (~50%) no molecular markers
3. Einstein/Montefiore Head and Neck Cancer Research Group 5/21/2010 Science at the heart of medicine Programmatic Goals: Predict tumor behavior Optimize treatment selection Identify potential new therapeutic targets Einstein Head and Neck Cancer Research Group: Belbin et al. (2007). Head and neck cancer: reduce and integrate for optimal outcome. Cytogenet Genome Res 118:92–109.
6. Differential DNA methylation in OPSCC 5/21/2010 Science at the heart of medicine r2=0.96 CpG loci within classically defined CpG island (20,007 loci) CpG loci outside of classically defined CpG island (7,572 loci)
8. Distribution of differentially methylated CpG loci on chromosomes 18. Data points are plotted as the average difference in beta between OPSCC tumor and normal mucosa for the 24 patients in Patient Set 1. Points above the ideogram are identified as hypermethylated in OPSCC; those below the ideogram are identified as hypomethylated. 5/21/2010 Science at the heart of medicine
9. 5/21/2010 Science at the heart of medicine Distribution of differentially methylated CpG loci on chromosomes 19. Data points are plotted as the average difference in beta between OPSCC tumor and normal mucosa for the 24 patients in Patient Set 1. Points above the ideogram are identified as hypermethylated in OPSCC; those below the ideogram are identified as hypomethylated.
10. 5/21/2010 Science at the heart of medicine Distribution of differentially methylated CpG loci on chromosomes 19. Data points are plotted as the average difference in beta between OPSCC tumor and normal mucosa for the 24 patients in Patient Set 1. Points above the ideogram are identified as hypermethylated in OPSCC; those below the ideogram are identified as hypomethylated.
11. Can ZNF671 be pharmacologically re-expressed in a model system? 5/21/2010 Science at the heart of medicine FaDu manipulate expression and study phenotype study mechanism in a model system Belbin et al. (2010). Aberrant DNA Methylation of ZNF Family Nucleic Acid Binding Protein Genes on Chromosome 19 in Oropharyngeal Squamous Cell Carcinoma. Submitted to American Journal of Pathology .
13. A Computational Approach for HNSCC Biomarker Discovery 5/21/2010 Science at the heart of medicine N0 N+ N+ N0 Support Vector Machine (SVM): machine learning algorithm used to divide samples into predefined groups based on a set of attributes
18. 12 out of 36 OP patientsNodal metastasis at diagnosis (N+ vs N0) 38 out of 51 OP patients 125 CpG signature Lleras et al. (2010). Signatures of DNA methylation are predictive of outcome in head and neck squamous cell carcinoma. Manuscript in preparation.
19. Future Directions Validate our predictive signatures in external patient populations to develop a clinically useful test for treatment selection at initial diagnosis. Test the functional significance of clinically relevant genes using the cell line model system. What about other anatomic sites? Can other –omics platforms be used to build prognostic signatures? (ex. gene expression, microRNA) 5/21/2010 Science at the heart of medicine
20. Acknowledgements 5/21/2010 Science at the heart of medicine Albert Einstein College of Medicine (www.einstein.yu.edu) Dr. Michael Prystowsky Dr. Geoffrey Childs Dr. Nicolas Schlecht Dr. Thomas Harris Aldo Massimi Nicole Kawachi Leslie Adrien Roberto Lleras Xin Zheng Quan Chen Montefiore Medical Center (www.montefiore.org) Dr. Richard Smith Dr. Brad Schiff Dr. Margie Brandwein-Gensler Dr. Chris Keller Dr. Missak Haigentz Dr. Madhur Garg Cathy Sarta Supported by : NIH Grant # R21CA104402 (TJB) NIH Grant # R21CA131648 (TJB) NIH Grant # R33CA103547 (MBP) Thyroid Head and Neck Cancer (THANC) Foundation (TJB)
